Eloctate is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Eloctate is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameEloctate
Authorized genericantihemophilic factor (recombinant) and fc fusion protein
Regular genericantihemophilic factor (recombinant) and fc fusion protein
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Eloctate?
The original
–
–

Brand nameThe maker’s card

HemAssist Copay Assistance Program

Savings card from Sanofi

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Sign up on consentrbdpatients.iassist.com 

Or call 1-833-723-5463. See the offer on sanofihemassist.com

In the maker’s words

“Get ELOCTATE for as little as $0.”

From the maker’s offer on sanofihemassist.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Eloctate itself, from the same company, sold without the brand name, and usually for less. For now Eloctate is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Eloctate is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

ELOCTATE, Antihemophilic Factor (Recombinant), Fc Fusion Protein, is a recombinant DNA derived, antihemophilic factor indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
  • Routine prophylaxis to reduce the frequency of bleeding episodes.

Limitation of Use

ELOCTATE is not indicated for the treatment of von Willebrand disease.

Source: the FDA label for Eloctate (Bioverativ Therapeutics Inc.), May 5, 2023. Full label on DailyMed 

Good to know